drugset / Trial / NCT05001516
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
Timeline
- Start
- 2021-12-29
- Primary completion
- 2024-01-04
- Completion
- 2024-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPX4589 | Other / unclassified | 0.2 mg/kg | Intravenous |
| Subject | TPX4589 | Other / unclassified | 0.4 mg/kg | Intravenous |
| Subject | TPX4589 | Other / unclassified | 0.8 mg/kg | Intravenous |
| Subject | TPX4589 | Other / unclassified | 1.6 mg/kg | Intravenous |
| Subject | TPX4589 | Other / unclassified | 2.4 mg/kg | Intravenous |
| Subject | TPX4589 | Other / unclassified | 2.8 mg/kg | Intravenous |